Ingrid Delaet Sells 623 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 623 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $149.29, for a total value of $93,007.67. Following the completion of the sale, the insider now owns 3,442 shares in the company, valued at $513,856.18. The trade was a 15.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, December 31st, Ingrid Delaet sold 272 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $138.10, for a total value of $37,563.20.
• On Tuesday, December 17th, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00.

Neurocrine Biosciences Stock Down 0.8 %

NBIX stock opened at $151.20 on Thursday. The business’s 50-day simple moving average is $137.92 and its 200 day simple moving average is $131.51. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The company has a market cap of $15.31 billion, a PE ratio of 40.54 and a beta of 0.33.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. BMO Capital Markets lowered their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Wedbush reaffirmed an “outperform” rating and issued a $148.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. UBS Group upped their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $166.85.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NBIX. Cetera Investment Advisers boosted its holdings in Neurocrine Biosciences by 7.9% during the second quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock valued at $979,000 after purchasing an additional 519 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter valued at $510,000. Handelsbanken Fonder AB raised its stake in shares of Neurocrine Biosciences by 20.7% in the third quarter. Handelsbanken Fonder AB now owns 26,867 shares of the company’s stock worth $3,096,000 after acquiring an additional 4,600 shares during the last quarter. GAMMA Investing LLC raised its position in Neurocrine Biosciences by 11.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,738 shares of the company’s stock worth $200,000 after purchasing an additional 185 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of Neurocrine Biosciences by 15.1% during the third quarter. CWM LLC now owns 7,884 shares of the company’s stock valued at $908,000 after acquiring an additional 1,035 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.